Clinical Trials Directory

Trials / Completed

CompletedNCT03040492

Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risk

Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risks in Alabama Population

Status
Completed
Phase
Study type
Observational
Enrollment
200 (actual)
Sponsor
University of Alabama at Birmingham · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to discover whether certain Vitamin D Receptor (VDR) gene polymorphisms are associated with an increased risk of cutaneous basal cell carcinoma (BCC) and/or cutaneous squamous cell carcinoma (SCC) in an Alabama population. Participant demographic information such as physical characteristics (e.g., ethnicity), family history, and cancer diagnosis will be collected in order to determine if there are relationships between the gene polymorphisms, cancer diagnosis, and these characteristics.

Detailed description

The purpose of this study is to discover whether certain Vitamin D Receptor (VDR) gene polymorphisms are associated with an increased risk of cutaneous basal cell carcinoma (BCC) and/or cutaneous squamous cell carcinoma (SCC) in an Alabama population. Participant demographic information such as physical characteristics (e.g., ethnicity), family history, and cancer diagnosis will be collected in order to determine if there are relationships between the gene polymorphisms, cancer diagnosis, and these characteristics. By identifying the VDR polymorphisms for the Apa1, Taq1, Bsm1, and Fok1 genes within the participant population and comparing the genotypes to controls, the investigators hope to demonstrate which gene polymorphisms indicate an increased risk for SCC or BCC. Inclusion- patients with a non-melanoma skin cancer. Participants must be 50 years old or older. Controls- patients without non-melanoma skin cancer and who have no family history of skin cancer. They must also be 50 years old or older; Inclusion for both groups- English speakers and patients at the Kirklin Clinic during the months of our data collection. Exclusion criteria will be patients younger than 50 years old or who have a diagnosis of melanoma or other type of cancer, or who are non-English speakers.

Conditions

Timeline

Start date
2012-10-31
Primary completion
2013-06-30
Completion
2017-06-30
First posted
2017-02-02
Last updated
2025-09-08

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03040492. Inclusion in this directory is not an endorsement.